Clinical Trial Update: Selective HDAC6 Inhibitor ACY-241 in Combination With Ipilimumab and Nivolumab [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the selective HDAC6 inhibitor ACY-241 in combination with ipilimumab and nivolumab for malignant melanoma has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• ACY-241
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Celgene | Conditions: Malignant Melanoma | Phase 1 | Status: COMPLETED